1224 infection control & hospital epidemiology october 2015, vol. 36, no. 10
with the human immunodeficiency virus. Int J Tuberc Lung Dis 2011;15:465–470.
30. Nguyen LT, Hamilton CD, Xia Q, Stout JE. Mortality before or during treatment among tuberculosis patients in North Carolina, 1993–2003. Int J Tuberc Lung Dis 2011;15:257–262.
31. Horne DJ, Hubbard R, Narita M, Exarchos A, Park DR, Goss CH. Factors associated with mortality in patients with tuberculosis. BMC Infect Dis 2010;10:258.
32. Nahid P, Jarlsberg LG, Rudoy I, et al. Factors associated with mortality in patientswith drug-susceptible pulmonary tuberculosis. BMC Infect Dis 2011;11:1. doi:1471-2334-11-1.
33. Kattan JA, Sosa LE, Lobato MN. Tuberculosis mortality: death from a curable disease, Connecticut, 2007–2009. Int J Tuberc Lung Dis 2012;16:1657–1662.
34. Pascopella L, Barry PM, Flood J, DeRiemer K. Death with tuberculosis in California, 1994–2008. Open Forum Infectious Diseases 2014;1(3):ofu090.
35. Bock NN, McGowan JE Jr, Ahn J, Tapia J, Blumberg HM. Clinical predictors of tuberculosis as a guide for a respiratory isolation policy. Am J Respir Crit Care Med 1996;154:1468–1472.
36. Gaeta TJ, Webheh W, Yazji M, Ahmed J, Yap W. Respiratory isolation of patients with suspected pulmonary tuberculosis in an inner-city hospital. Acad Emerg Med 1997;4:138–141.
37. El-Solh A, Mylotte J, Sherif S, Serghani J, Grant BJ. Validity of a decision tree for predicting active pulmonary tuberculosis. Am J Respir Crit Care Med 1997;155:1711–1716.
38. Wisnivesky JP, Kaplan J, Henschke C, McGinn TG, Crystal RG. Evaluation of clinical parameters to predict Mycobacterium tuberculosis in inpatients. Arch Intern Med 2000;160:2471–2476.
39. Wisnivesky JP, Henschke C, Balentine J, Willner C, Deloire AM, McGinn TG. Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis. Arch Intern Med 2005;165:453–457.
40. Moran GJ, Barrett TW, Mower WR, et al. Decision instrument for the isolation of pneumonia patients with suspected pulmonary tuberculosis admitted through US emergency departments. Ann Emerg Med 2009;53:625–632.
41. Rakoczy KS, Cohen SH, Nguyen HH. Derivation and validation of a clinical prediction score for isolation of inpatients with suspected pulmonary tuberculosis. Infect Control Hosp Epidemiol 2008;29:927–932.
42. Aguilar J, Yang JJ, Brar I, Markowitz N. Clinical prediction rule for respiratory isolation of patients with suspected pulmonary tuber- culosis. Infectious Diseases in Clinical Practice 2009;17:317–322.
43. Pegues CF, Johnson DC, Pegues DA, Spencer M, Hopkins CC. Implementation and evaluation of an algorithm for isolation of patients with suspected pulmonary tuberculosis. Infect Control Hosp Epidemiol 1996;17:412–418.
44. Mylotte JM, Rodgers J, Fassl M, Seibel K, Vacanti A. Derivation and validation of a pulmonary tuberculosis prediction model. Infect Control Hosp Epidemiol 1997;18:554–560.
45. Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 2006;3:103–110.
46. Amplified Mycobacterium Tuberculosis Direct Test [package insert]. San Diego, CA: Gen-Probe Incorporated; 2013.
47. Lin SY, Rodwell TC, Victor TC, et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tubercu- losis in clinical isolates and clinical specimens. J Clin Microbiol 2014;52:475–482.
48. Centers for Disease Control and Prevention. Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use— United States, 2013. MMWR 2013;62:821–827.
49. Centers for Disease Control and Prevention. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR 2009;58:7–10.
50. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller WC. Assessment by meta-analysis of PCR for diagnosis of smear- negative pulmonary tuberculosis. J Clin Microbiol 2003;41: 3233–3240.
51. Greco S, Rulli M, Girardi E, Piersimoni C, Saltini C. Diagnostic accuracy of in-house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and metaregression. J Clin Microbiol 2009;47:569–576.
52. Greco S, Girardi E, Navarra A, Saltini C. Current evidence on diagnostic accuracy of commercially based nucleic acid amplifi- cation tests for the diagnosis of pulmonary tuberculosis. Thorax 2006;61:783–790.
53. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012;64:580–588.
54. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tubercu- losis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014;1:CD009593.
55. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how-to'; practical considerations. Geneva, Switzerland: WHO; 2011. World Health Organization website.
http://www.tbevidence.org/tbevidence_old_site_files/ documents/policies/WHO%20Rapid%20Implementation%20of %20Xpert.pdf. Accessed April 29, 2015.
56. Catanzaro A, Perry S, Clarridge JE, et al. The role of clinical sus- picion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA 2000;283:639–645.
57. Piersimoni C, Nista D, Zallocco D, Galassi M, Cimarelli ME, Tubaldi A. Clinical suspicion as a primary guidance to use com- mercial amplification tests for rapid diagnosis of pulmonary tuberculosis. Diagn Microbiol Infect Dis 2005;53:195–200.
58. Lim TK, Mukhopadhyay A, Gough A, et al. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. Chest 2003; 124:902–908.
59. Lim TK, Gough A, Chin NK, Kumarasinghe G. Relationship between estimated pretest probability and accuracy of automated Mycobacterium tuberculosis assay in smear-negative pulmonary tuberculosis. Chest 2000;118:641–647.
60. Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013;1:462–470.
61. BoylesTH, Hughes J, Cox V, Burton R, Meintjes G,MendelsonM. False-positive Xpert(R) MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis 2014;18:876–878.
62. Lippincott CK, Miller MB, Popowitch EB, Hanrahan CF, Van RA. Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. Clin Infect Dis 2014;59:186–192.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140